Mesothelioma Clinical Trials

31 studies are recruiting for mesothelioma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

   This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Arizona, Phoenix, Arizona

   Locations

   20 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07277413 on ClinicalTrials.gov

2. A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

   This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors who have progressed on or are intolerant to standard therapies. The stud…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   4 in total

   Run by

   SHY Therapeutics

   See if you can join NCT07705334 on ClinicalTrials.gov

3. Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

   Background: A germline mutation is a change to a person s genes that is carried through their DNA. These mutations can be passed on from parents to their offspring. Germline mutations in a gene called BAP1 are linked to the development of mesothelioma and other cancers. Researchers want to follow p…

   Stage

   Not phased

   Ages

   30 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04431024 on ClinicalTrials.gov

4. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

   Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Banner Health, Gilbert, Arizona

   Locations

   16 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT04981119 on ClinicalTrials.gov

5. Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

   This is a Phase II study to determine the rate of stabilization or disease improvement from investigational decitabine/cedazuridine (INQOVI) treatment in subjects with BRCA1-Associated Protein-1 (BAP1) Cancer Predisposition Syndrome (CPDS) and subclinical, early-stage mesothelioma. Progression-free…

   Stage

   Phase 2

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05960773 on ClinicalTrials.gov

6. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Phoenix, Arizona

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

7. Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

   Background: * Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. * Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant pleural mesothelioma is the most common of these, comprising of 8…

   Stage

   Not phased

   Ages

   2 to 100

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT01950572 on ClinicalTrials.gov

8. Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1

   Background: -A gene provides instructions to the body. Mutated genes can sometimes cause cancer. Germline mutations are those people are born with. These mutations in the BAP1 gene can cause mesothelioma and other cancers. Researchers want to study people with germline mutations of BAP1 and other g…

   Stage

   Not phased

   Ages

   2 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03830229 on ClinicalTrials.gov

9. Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

   Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma. Researchers are developing a ne…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06885697 on ClinicalTrials.gov

10. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USOR HonorHealth, Phoenix, Arizona

    Locations

    66 in total

    Run by

    Genmab

    See if you can join NCT05579366 on ClinicalTrials.gov

11. A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

    The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments t…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Chicago (Data Collection Only), Chicago, Illinois

    Locations

    13 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06057935 on ClinicalTrials.gov

12. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

    This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway altera…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Phoenix, Arizona

    Locations

    15 in total

    Run by

    Nuvectis Pharma, Inc.

    See if you can join NCT05873686 on ClinicalTrials.gov

13. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

    Stage

    Phase 1

    Ages

    18 to 90

    Site

    University of Miami, Miami, Florida

    Locations

    11 in total

    Run by

    Perspective Therapeutics

    See if you can join NCT06710756 on ClinicalTrials.gov

14. Integrated Cancer Repository for Cancer Research

    The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct char…

    Stage

    Not phased

    Ages

    19 to 110

    Site

    Advent Health, Greenwood Village, Colorado

    Locations

    42 in total

    Run by

    University of Nebraska

    See if you can join NCT02012699 on ClinicalTrials.gov

15. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

    The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner Health, Gilbert, Arizona

    Locations

    12 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT06051695 on ClinicalTrials.gov

16. A Study of Sacituzumab Govitecan in People With Mesothelioma

    Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06477419 on ClinicalTrials.gov

17. 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

    Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. [18F]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imaging scan. Researchers …

    Stage

    Phase 2

    Ages

    18 to 120

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT06503146 on ClinicalTrials.gov

18. Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

    This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT03683680 on ClinicalTrials.gov

19. A 2-part Phase 1/2 Open-label Trial on ODM-212

    An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, Irving, Texas

    Locations

    2 in total

    Run by

    Orion Corporation, Orion Pharma

    See if you can join NCT07563738 on ClinicalTrials.gov

20. A Study of VET3-TGI in Patients With Solid Tumors

    VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or whe…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC/Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    7 in total

    Run by

    KaliVir Immunotherapeutics

    See if you can join NCT06444815 on ClinicalTrials.gov

21. Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

    This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which n…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

    Locations

    12 in total

    Run by

    Vivace Therapeutics, Inc

    See if you can join NCT04665206 on ClinicalTrials.gov

22. Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

    This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment stra…

    Stage

    Not phased

    Ages

    Any age

    Site

    The Ohio State University Wexner Medical Center, Columbus, Ohio

    Run by

    Mohamed Abdel-Rahman

    See if you can join NCT04792463 on ClinicalTrials.gov

23. Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma

    Purpose of the study: The main purpose of this research study is to see if a surgery procedure (limited partial pleurectomy and decortication) helps symptoms in people who have cancer that is unresectable that might not be able to be removed completely. This is called unresectable cancer. This stud…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT07126509 on ClinicalTrials.gov

24. VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

    This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curat…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    Providence Medical Foundation (site 209), Santa Rosa, California

    Locations

    15 in total

    Run by

    VM Oncology, LLC

    See if you can join NCT03556228 on ClinicalTrials.gov

25. MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI

    In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Run by

    Brigham and Women's Hospital

    See if you can join NCT05730816 on ClinicalTrials.gov